The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature - PubMed (original) (raw)
Review
. 2012 Jun 1;18(11):3022-9.
doi: 10.1158/1078-0432.CCR-11-3216. Epub 2012 Apr 17.
Affiliations
- PMID: 22510350
- DOI: 10.1158/1078-0432.CCR-11-3216
Review
The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature
Ronald J deLeeuw et al. Clin Cancer Res. 2012.
Abstract
CD8+ tumor-infiltrating lymphocytes (TIL) are associated with survival in a variety of cancers. A second subpopulation of TIL, defined by forkhead box protein P3 (FoxP3) expression, has been reported to inhibit tumor immunity, resulting in decreased patient survival. On the basis of this premise, several groups are attempting to deplete FoxP3+ T cells to enhance tumor immunity. However, recent studies have challenged this paradigm by showing that FoxP3+ T cells exhibit heterogeneous phenotypes and, in some cohorts, are associated with favorable prognosis. These discrepant results could arise from differences in study methodologies or the biologic properties of specific cancer types. Here, we conduct the first systematic review of the prognostic significance of FoxP3+ T cells across nonlymphoid cancers (58 studies from 16 cancers). We assessed antibody specificity, cell-scoring strategy, multivariate modeling, use of single compared with multiple markers, and tumor site. Two factors proved important. First, when FoxP3 was combined with one additional marker, double-positive T cells were generally associated with poor prognosis. Second, tumor site had a major influence. FoxP3+ T cells were associated with poor prognosis in hepatocellular cancer and generally good prognosis in colorectal cancer, whereas other cancer types were inconsistent or understudied. We conclude that FoxP3+ T cells have heterogeneous properties that can be discerned by the use of additional markers. Furthermore, the net biologic effects of FoxP3+ T cells seem to depend on the tumor site, perhaps reflecting microenvironmental differences. Thus, depletion of FoxP3+ T cells might enhance tumor immunity in some patient groups but be detrimental in others.
Similar articles
- Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, Watanabe G, Tada H, Suzuki A, Ohuchi N, Ishida T. Miyashita M, et al. Breast Cancer Res. 2015 Sep 4;17(1):124. doi: 10.1186/s13058-015-0632-x. Breast Cancer Res. 2015. PMID: 26341640 Free PMC article. - Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.
Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S. Saito T, et al. Nat Med. 2016 Jun;22(6):679-84. doi: 10.1038/nm.4086. Epub 2016 Apr 25. Nat Med. 2016. PMID: 27111280 - CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E, Hase K, Hashiguchi Y, Sekizawa A, Ueno H, Shikina A, Kajiwara Y, Kobayashi H, Ishiguro M, Yamamoto J. Shinto E, et al. Ann Surg Oncol. 2014 Jun;21 Suppl 3:S414-21. doi: 10.1245/s10434-014-3584-y. Epub 2014 Feb 25. Ann Surg Oncol. 2014. PMID: 24566864 - The expression of FOXP3 and its role in human cancers.
Jia H, Qi H, Gong Z, Yang S, Ren J, Liu Y, Li MY, Chen GG. Jia H, et al. Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):170-178. doi: 10.1016/j.bbcan.2018.12.004. Epub 2019 Jan 7. Biochim Biophys Acta Rev Cancer. 2019. PMID: 30630091 Review. - Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis.
Shang B, Liu Y, Jiang SJ, Liu Y. Shang B, et al. Sci Rep. 2015 Oct 14;5:15179. doi: 10.1038/srep15179. Sci Rep. 2015. PMID: 26462617 Free PMC article. Review.
Cited by
- Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target.
Huo MH, Adeerjiang Y, Abulitipu A, Khan U, Li XX, Zhang L, Tian Y, Jiang S, Xu CC, Chao XZ, Yang YF, Zhang JX, Du GL. Huo MH, et al. Front Oncol. 2024 Oct 29;14:1325575. doi: 10.3389/fonc.2024.1325575. eCollection 2024. Front Oncol. 2024. PMID: 39534095 Free PMC article. Review. - DNA Methylation-Derived Immune Cell Proportions and Cancer Risk in Black Participants.
Semancik CS, Zhao N, Koestler DC, Boerwinkle E, Bressler J, Buchsbaum RJ, Kelsey KT, Platz EA, Michaud DS. Semancik CS, et al. Cancer Res Commun. 2024 Oct 1;4(10):2714-2723. doi: 10.1158/2767-9764.CRC-24-0257. Cancer Res Commun. 2024. PMID: 39324671 Free PMC article. - Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression.
Khaddour K, Murakami N, Ruiz ES, Silk AW. Khaddour K, et al. Cancers (Basel). 2024 Sep 4;16(17):3083. doi: 10.3390/cancers16173083. Cancers (Basel). 2024. PMID: 39272941 Free PMC article. Review. - The relationship between the tertiary lymphoid structure and immune-infiltrating cells in gastrointestinal cancers: A systematic review and meta-analysis.
Yu A, Fan Z, Ma L, Tang J, Liu W, Han Z, Wang H. Yu A, et al. Immun Inflamm Dis. 2024 Sep;12(9):e70003. doi: 10.1002/iid3.70003. Immun Inflamm Dis. 2024. PMID: 39259184 Free PMC article. - Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.
Wang Z, Zhou L, Wu X. Wang Z, et al. Oncol Res. 2024 Aug 23;32(9):1479-1516. doi: 10.32604/or.2024.048564. eCollection 2024. Oncol Res. 2024. PMID: 39220130 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials